Corbus Pharmaceuticals is actively conducting several key clinical studies across its therapeutic pipeline. This includes clinical trials evaluating CRB-701 (SYS6002) in patients with advanced solid tumors—such as head and neck squamous cell carcinoma and cervical cancer—under FDA Fast Track designations. Additionally, the company is running the CANYON-1 Phase 1b clinical trial evaluating CRB-913 for the treatment of obesity.